Lifecare Achieves Major Breakthrough in the Attempt to Miniaturize the SencellGlucose Sensor Lifecare is developing an implantable continuous glucose sensor based on itsproprietary osmotic pressure cell technology. One core element of the glucosesensor is a pressure transducer, which translates the glucose-induced osmoticpressure change in the measurement chamber into a transmittable electronicsignal. Until now, the size of the pressure transducer prevented furtherminiaturization of the osmotic pressure chamber and of the final device.Lifecare has partnered with cantiMED, Darmstadt, Germany, a global leader innanotechnology solutions, to solve the problem. Scientists from both companiesare pleased to report that the nanosensor technology has been shown inlaboratory experiments to accurately measure pressure changes derived fromsubstantially smaller osmotic pressure chambers. The working prototypelaboratory sensor model had only a fourth of the size of the actual version, andfurther downsizing to less than a tenth is warranted based on the actualresults. "These findings represent a major break-through for our entire glucose sensordevelopment" says Lifecare Chairman of the Board Christian Saure, "We can nowcontinue to significantly down-size our device by miniaturizing the coreglucose-sensing element of our device with the smallest pressure sensor of theworld, which will ultimately lead to significant competitive advantages for thefinal product."